20/20 Biolabs (AIDX) Annual Balance Sheets

Annual · GAAP · USD millions
Access AIDX quarterly Balance Sheets →
The table below presents a historical view of 20/20 Biolabs's balance sheet, supporting analysis of financial position trends.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2024)
Assets
Cash & cash equivalent1.78
Cash & Short-term Investments1.00
Accounts receivable0.14
Inventories0.05
Total loans net0.07
Total Current Assets2.03
Equipment/Property/Plant Net0.58
Intangible Assets0.21
Tax Assets, Noncurrent7.03
Total Assets3.58
Liabilities
Accounts Payable0.37
Accrued Liabilities, Current0.35
Total Current Liabilities1.36
Total Long-term Debt0.00
Total Liabilities2.08
Stockholders' Equity
Common Stock Value0.05
Additional Paid In Capital Common Stock30.95
Retained Earnings / Accumulated Deficit-29.51
Common Stockholder's Equity1.51
Total Stockholder's Equity1.51
Liabilities & Stockholder's Equity3.58
4 historic quarters locked

Sign in to unlock the full 20/20 Biolabs balance sheet history.

About 20 20 Biolabs Inc Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001213900-26-037667

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License